Screener
CytomX Therapeutics CTMX Accrued Expenses
Accrued Expenses at other companies
Other financials
Where this comes from
Reported directly by CytomX Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AccruedLiabilitiesCurrent.
The source filing: CytomX Therapeutics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:05 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-337950
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Liabilities and Stockholders' Equity | ||
| Current liabilities: | ||
| Accounts payable | $1,939 | $1,301 |
| Accrued liabilities | 12,353 | 14,197 |
| Operating lease liabilities - short-term | 1,496 | 4,240 |
| Deferred revenue, current portion | 24,073 | 26,877 |
| Total current liabilities | 39,861 | 46,615 |
| Deferred revenue, net of current portion | 30,617 | 1,590 |
Item 1. Condensed Financial Statements (Unaudited)
FAQ
- What is CytomX Therapeutics's accrued expenses?
- CytomX Therapeutics (CTMX) reported accrued expenses of $12.35M in Q2 2026.
- How has CytomX Therapeutics's accrued expenses changed year-over-year?
- CytomX Therapeutics's accrued expenses increased by 7.4% year-over-year, from $11.5M to $12.35M.
- What is the long-term trend for CytomX Therapeutics's accrued expenses?
- Over 5 years (2020 to 2025), CytomX Therapeutics's accrued expenses has grown at a -9.2% compound annual growth rate (CAGR), from $23.06M to $14.2M.
- What does accrued expenses mean?
- Expenses incurred but not yet paid or invoiced — interest accruals, tax accruals, warranty reserves, and other timing differences.
Ask your AI about CytomX Therapeutics's accrued expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude